Lenvatinib (Lenvima) Survey
The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing liver cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for hepatocellular carcinoma called Lenvatinib (Lenvima).
At this time we are primarily looking for patients with hepatocellular carcinoma (primary liver cancer) and their caregivers who would be interested in participating in this survey. If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.
The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.
The survey will be available starting now and remain open until February 14th, 2019.
Thank you for your participation.
